Published by Global Banking & Finance Review®
Posted on February 24, 2026
1 min readLast updated: April 2, 2026
Add as preferred source on GoogleNovo Nordisk will lower U.S. list prices for Wegovy and Ozempic on Jan 1, 2027—up to 50% and 35%—setting a $675 monthly price. Rybelsus is included; the aim is greater affordability for patients and payers. (prnewswire.com)
COPENHAGEN, Feb 24 (Reuters) - Danish drugmaker Novo Nordisk said on Tuesday it plans to slash the U.S. list prices of its blockbuster weight-loss drug Wegovy and diabetes drug Ozempic by up to 50% and 35% respectively as of January next year.
(Reporting by Louise Rasmussen, editing by Terje Solsvik)
Novo Nordisk plans to cut U.S. list prices for its semaglutide drugs Wegovy and Ozempic from January 1, 2027, with Wegovy down about 50% and Ozempic about 35%, to $675 per month. (prnewswire.com)
The new list prices start January 1, 2027, and cover Wegovy, Ozempic, and Rybelsus in the U.S. market. (prnewswire.com)
It’s designed to help patients whose costs are tied to list prices, such as those with high deductibles or coinsurance. Existing direct self‑pay programs are unchanged. (prnewswire.com)
Explore more articles in the Finance category
